SPXE:ARCA-ProShares S&P 500 Ex-Energy

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 63.791

Change

+0.02 (+0.03)%

Market Cap

USD 9.07M

Volume

100.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks investment results, before fees and expenses that track the performance of the S&P 500? Ex-Energy Index (the "index"). Under normal circumstances, the fund will invest at least 80% of its total assets in component securities. The index seeks to provide exposure to the companies of the S&P 500? Index (the "S&P 500?") with the exception of those companies included in the Energy Sector.

Inception Date: 22/09/2015

Primary Benchmark: S&P 500® Ex-Energy USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 0.27%

Management Expense Ratio: 0.27 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-15 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SCYB Schwab Strategic Trust 0.00 %

+0.15 (+0.29%)

N/A

ETFs Containing SPXE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.39% 59% D- 74% C
Dividend Return 0.91% 74% C 26% F
Total Return 22.29% 62% D 72% C
Trailing 12 Months  
Capital Gain 12.45% 79% B- 83% B
Dividend Return 1.64% 68% D+ 31% F
Total Return 14.09% 82% B 82% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 9.25% 96% N/A 64% D
Dividend Return 10.51% 83% B 63% D
Total Return 1.27% 44% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 9.07% 30% F 88% B+
Risk Adjusted Return 115.87% 74% C 96% N/A
Market Capitalization 9.07M 26% F 5% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.